GeoVax to initiate Phase 1 combination therapy trial with MVA62B
Category: #health  By Pankaj Singh  Date: 2020-08-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

GeoVax to initiate Phase 1 combination therapy trial with MVA62B

GeoVax Labs, Inc., a U.S-based biotechnology firm that focuses on vaccines and immunotherapies for cancer and other infectious, has recently revealed that it has initiated the Phase 1 clinical trial of combination therapy in HIV-infected adults. The combination therapy will be using the company’s new boost component MVA62B. 

Reportedly, the trial would involve active participation of various researchers that will be led by Dr. Steven Deeks, a professor at the UCSF and a faculty member at the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. The study is being funded by The Foundation for AIDS Research, amfAR. The main motive of this study is to induce remission in patients suffering from HIV.

According to reports, the trial would enroll 20 HIV-positive patients who are on effective and stable antiretroviral therapy (ART). GeoVax will be offering MVA62B, a novel boost component that would be combined with its HIV prevention vaccine, GOVX-B11.

Speaking on the move, Dr. Steven Deeks said that this Phase 1 study would come as one of the most inclusive trials till this date to evaluate the efficiency of synergistic methods to regulate HIV infection. The main focus here is to test the tolerability and safety of the combination therapy and to analyze the viral load ’set-point’ in between of a treatment interruption. 

Meanwhile, the secondary endpoint emphasizes on determining changes in viral reservoir status and immune responses. The institute is delighted to partner with GeoVax for this study and is looking forward to collaborating with GeoVax scientists to progress this trial. 

As for Harriet Robinson, Ph.D., CSO Emeritus, GeoVax, the company has managed to previously establish the result of its HIV vaccine and hopes to see the same progressive result for UCSF’s therapeutic study where it would be combined with its MVA62B vaccine. 

Source Credit: https://www.globenewswire.com/news-release/2020/08/24/2082657/0/en/GeoVax-Announces-Clinical-Trial-Initiation-of-Novel-Combination-Therapy-Utilizing-MVA62B-to-Induce-Remission-in-HIV-Positive-Patients.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

GENFIT & LabCorp Come Together to Develop a Diagnostic Test for NASH
GENFIT & LabCorp Come Together to Develop a Diagnostic Test for NASH
By Pankaj Singh

GENFIT, a biopharmaceutical company committed to improving the lives of patients suffering from liver and metabolic diseases, and LabCorp®, a leading life sciences enterprise focuses on guiding patient care decisio...

RADLogics obtains FDA's approval for AI-based chest X-Ray App
RADLogics obtains FDA's approval for AI-based chest X-Ray App
By Pankaj Singh

RADLogics Inc., a healthcare software company developing AI-powered solutions has reportedly received 510(k) clearance from the US FDA (Food and Drug Administration) for its latest AI-Powered chest X-ray pneumothorax a...

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...